ACVR2B activin A receptor type 2B
ENSG00000114739 · protein coding · Open Targets profile
Transmembrane serine/threonine kinase activin type-2 receptor forming an activin receptor complex with activin type-1 serine/threonine kinase receptors (ACVR1, ACVR1B or ACVR1c). Transduces the activin signal from the cell surface to the cytoplasm and is thus regulating many physiological and pathological processes including neuronal differentiation and neuronal survival, hair follicle development and cycling, FSH production by the pituitary gland, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. Activin is also thought to have a paracrine or autocrine role in follicular development in the ovary. Within the receptor complex, the type-2 receptors act as a primary activin receptors (binds activin-A/INHBA, activin-B/INHBB as well as inhibin- A/INHA-INHBA). The type-1 receptors like ACVR1B act as downstream transducers of activin signals. Activin binds to type-2 receptor at the plasma membrane and activates its serine-threonine kinase. The activated receptor type-2 then phosphorylates and activates the type-1 receptor. Once activated, the type-1 receptor binds and phosphorylates the SMAD proteins SMAD2 and SMAD3, on serine residues of the C-terminal tail. Soon after their association with the activin receptor and subsequent phosphorylation, SMAD2 and SMAD3 are released into the cytoplasm where they interact with the common partner SMAD4. This SMAD complex translocates into the nucleus where it mediates activin-induced transcription. Inhibitory SMAD7, which is recruited to ACVR1B through FKBP1A, can prevent the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. Activin signal transduction is also antagonized by the binding to the receptor of inhibin-B via the IGSF1 inhibin coreceptor. .
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand, High-Quality Ligand, Med-Quality Pocket, Druggable Family
- Antibody
- Advanced Clinical, UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
- PROTAC
- Database Ubiquitination, Small Molecule Binder
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.2766900062561035 (upper bound 0.41029998660087585). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 19 registry trials, updated in the last three years, of the most advanced drugs against ACVR2B (dibotermin alfa, bimagrumab), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Matthew GreivesThe University of Texas Health Science Center, Houston · 1 of 1 trials Phase 2+
- Diel PeterOrthopädie Sonnenhof, Bern · 0 of 1 trials Phase 2+
- Jumi HanCGBio Inc. · 0 of 1 trials Phase 2+
- Peter PassiasNYU Langone Medical Center · 0 of 1 trials Phase 2+
- Wenjie RenThe First Affiliated Hospital of Xinxiang Medical College · 0 of 1 trials Phase 2+
Registry trials of dibotermin alfa, bimagrumab updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 12 of 17 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 2 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
13 trials of drugs against ACVR2B were stopped early; 5 give no reason
Terminated, withdrawn and suspended interventional trials of dibotermin alfa, bimagrumab, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 13 most recent of 13.
- withdrawn · 2025-09-24 · Eli Lilly and Company · Bimagrumab, Bimagrumab Placebo“Study terminated for strategic business reasons”
- terminated · 2023-05-17 · Medtronic Spinal and Biologics · matched by the registry's drug synonymsNo reason given
- terminated · 2023-05-17 · Medtronic Spinal and Biologics · matched by the registry's drug synonymsNo reason given
- withdrawn · 2022-11-14 · Ross Leighton · matched by the registry's drug synonyms“Study never started”
- terminated · 2021-10-27 · University of Alabama at Birmingham · matched by the registry's drug synonyms“Insufficient enrollment to meet the statistical requirements”
- terminated · 2019-08-28 · Virtua Health, Inc. · matched by the registry's drug synonyms“PI left the institution”
- terminated · 2018-10-25 · St. Louis University · matched by the registry's drug synonyms“Enrollment too slow”
- withdrawn · 2018-09-13 · Medtronic Spinal and Biologics · matched by the registry's drug synonymsNo reason given
- terminated · 2016-02-18 · Medtronic Spinal and Biologics · matched by the registry's drug synonyms“Due to study design challenges including DMC enrollment suspension as required by the protocol stopping rules and recommended changes to the surgical technique”
- terminated · 2015-01-21 · Medtronic Spinal and Biologics · matched by the registry's drug synonyms“Difficulty in patient recruitment”
- withdrawn · 2015-01-07 · Novartis Pharmaceuticals · matched by the registry's drug synonymsNo reason given
- terminated · 2013-08-02 · Medtronic Spinal and Biologics · matched by the registry's drug synonymsNo reason given
- terminated · 2013-02-28 · Wyeth is now a wholly owned subsidiary of Pfizer · matched by the registry's drug synonyms“Decision was taken by Wyeth Sr. Management to early terminate the 3100N7-210 study (terminate enrollment but complete follow-up).”
Paediatric incentives and obligations for ACVR2B's drugs
For dibotermin alfa, bimagrumab: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · ACVR2B is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: no · No EMA paediatric investigation plan decision names dibotermin alfa, bimagrumabRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names dibotermin alfa, bimagrumabRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Inductos: authorised since 9 Sept 2002Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA EPAR Inductos, 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of dibotermin alfa, bimagrumabRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 7 interventional studies of dibotermin alfa, bimagrumab include patients under 18; 1 is recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 2 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.
| Drug | Type | Highest stage | Indications | Source records |
|---|---|---|---|---|
| DIBOTERMIN ALFA | Protein | phase 4 | spinal fusion, tibia fracture, bone disorder, osteoporosis | Open Targets · ChEMBL |
| BIMAGRUMAB | Antibody | phase 3 | inclusion body myositis, acute myeloid leukemia by FAB classification, muscle atrophy, type 2 diabetes mellitus, Cachexia, sarcopenia, chronic obstructive pulmonary disease, Overweight, +1 more | Open Targets · ChEMBL |